Application of miR-155 as molecular marker in diagnosis of preeclampsia

Abstract

The invention discloses application of miR-155 as a molecular marker in diagnosis of preeclampsia (PE). The nucleotide sequence of miR-155 is shown as SEQ. ID. NO.1. By means of experiments, the invention finds that the expression of miR-155 in sera of PE patients is significantly enhanced compared with normal pregnant women, and the ratio of PE patients' serum miRNA to urine miRNA is significantly increased compared with a normal pregnancy group, and ROC mapping shows that miR-155 has medium diagnostic value on preeclampsia. Therefore, through determination of patients' peripheral circulation miR-155, and combination of the clinicopathological features thereof, the invention provides a reliable index and basis for diagnosis, treatment and disease assessment of preeclampsia.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, in particular to the application of miR-155 as a molecular marker in diagnosing preeclampsia. Background technique [0002] Preeclampsia (PE) is a common obstetric complication and one of the main causes of maternal and perinatal morbidity and mortality. In 2006, WHO released data showing that deaths due to PE or eclampsia accounted for 15%-20% of maternal deaths in developing countries. According to the severity of the disease, PE is divided into mild and severe; according to the time of onset, it is divided into early-onset and late-onset. [0003] The pathophysiology of PE can be divided into two stages: in the first stage, shallow implantation of villus leads to reduced placental perfusion; in the second stage, extensive activation and damage of vascular endothelial cells throughout the body of the pregnant woman leads to multiple organ dysfunction. At present, the pathogenesis of these...

AI Technical Summary

Problems solved by technology

24-hour urine protein quantification is an important basis for evaluating the severity of the disease. However, due to the rapid progression of PE, and 24-hour urine protein quantification often takes 1-2 days to make a definite diagnosis, it is not possible to use 24-hour urine protein quantification as the basis for diagnosis. Timely reflect the progress of PE patients

At the same time, due to the unclear pathogenesis of PE, there are no effective predictive indicators for clinical application. When pregnant women develop clinical symptoms such as hypertension and proteinuria, they often have developed to the advanced stage of the disease. Therefore, how to quickly and accurately evaluate the condition of PE patients is an important issue we face

Images